What Electrochemotherapy Is
Electrochemotherapy is a focal tumor treatment that combines a chemotherapy drug, usually bleomycin or cisplatin, with brief, precisely controlled electric pulses delivered directly to the tumor through specialized electrodes. The pulses temporarily open the cell membranes of tumor cells, letting much more of the chemotherapy drug enter them than would happen naturally. The result is dramatically increased local drug effect with very little systemic exposure.
In this article
- What Electrochemotherapy Is
- How the Mechanism Works
- Drug Selection: Bleomycin Versus Cisplatin
- What Tumors Are Treated
- Where Electrochemotherapy Fits in the Treatment Plan
- The Procedure Day
- Response and Repeat Treatment
- Cost and Access
- Comparing Electrochemotherapy to Other Modalities
- Adoption-Positive Framing
- Frequently Asked Questions
In human medicine, electrochemotherapy has been used in Europe for two decades to treat skin metastases from melanoma and other cancers. The veterinary application is more recent and is concentrated at specialty referral centers with the trained team and equipment. For dogs and cats with cutaneous or subcutaneous tumors that cannot be resected cleanly, electrochemotherapy pets options have expanded what is possible.
The procedure is performed under general anesthesia by a board-certified veterinary medical oncologist (DACVIM-Oncology) or a surgical-oncology team. It is not a daily medication, not a chemotherapy infusion, and not a radiation course. It is a focal, scheduled procedure designed to treat what can be physically reached with the electrode applicator.
How the Mechanism Works
Cell membranes are normally selective barriers. Bleomycin and cisplatin are both effective tumor cell killers when they enter the cell, but their entry through intact membranes is slow and limited. Electrochemotherapy uses electroporation, which is a series of short, intense electric pulses delivered through paired needle electrodes inserted into and around the tumor.
These pulses create transient pores in the membranes of all cells within the treatment field. With the chemotherapy drug already present in the tissue, far more drug enters the tumor cells than would otherwise occur. Bleomycin’s intracellular potency increases by hundreds-fold under electroporation; cisplatin sees a roughly tenfold increase. Tumor cells die quickly, and the local tissue mounts an inflammatory and immune response that may further support tumor clearance.
Drug Selection: Bleomycin Versus Cisplatin
Bleomycin is the more commonly used drug in veterinary electrochemotherapy because its dramatic potentiation by electroporation translates to strong tumor effect with a very low systemic dose. It is usually administered intravenously a few minutes before the electric pulses are applied. The systemic dose given is far lower than the dose used for conventional bleomycin chemotherapy, minimizing systemic side effects.
Cisplatin is used in select cases, often delivered as a direct intratumoral injection just before the pulses. The choice between drugs and the route depends on tumor type, tumor location, size, and the oncologist’s experience. Some protocols use both drugs sequentially in different tumor masses on the same patient.
What Tumors Are Treated
Electrochemotherapy is most useful for superficial tumors where surgery cannot achieve clean margins or where the patient is not a candidate for radical surgery. Common indications include incompletely resected mast cell tumors, soft tissue sarcomas with positive surgical margins, and recurrent skin tumors. It is also used in cats with feline injection site sarcoma in selected cases where wide surgical margins are not achievable.
Treatment depth is the main constraint. The electrode applicators typically penetrate one to two centimeters, so tumors much deeper than that are not good candidates. Tumors involving bone, joints, internal organs, or the body wall in ways that would compromise function are usually treated with other modalities. For tumors near the eye, mouth, or other sensitive structures, the specialist will weigh the risk-benefit carefully.
Where Electrochemotherapy Fits in the Treatment Plan
Electrochemotherapy is most often used as part of a multimodal plan. After a tumor has been removed surgically but the pathology shows narrow or positive margins, electrochemotherapy can be applied to the surgical bed to reduce local recurrence risk. For non-resectable cutaneous or subcutaneous masses, it can be used as a primary local therapy.
For mast cell tumors specifically, modern oncology now combines a deepening set of tools. Toceranib (Palladia) tyrosine kinase inhibitor for MCT and Stelfonta intratumoral tigilanol mesylate for MCT are alternatives or complements to electrochemotherapy depending on tumor characteristics. The decision is made by a DACVIM-Oncology specialist based on staging, grade, location, and the family’s goals.
The Procedure Day
The patient is admitted, anesthetized, and positioned for access to the tumor. General anesthesia is required because the electric pulses cause involuntary muscle contractions and are uncomfortable while delivered. The tumor and a small surrounding margin are clipped and prepped sterilely. Bleomycin is given intravenously, and after a brief wait for tissue distribution, the electroporation pulses are delivered through the electrode applicator at multiple positions to cover the entire tumor volume.
The procedure itself usually takes thirty to ninety minutes depending on tumor size and number of treatment fields. Recovery from anesthesia is the typical post-procedure period; the dog or cat usually goes home the same day or the next morning. The treated area is monitored over the following weeks for response and for local effects.
What to Expect Afterward
The treated tumor and surrounding tissue typically develop swelling, bruising, and a localized inflammatory response over the first one to two weeks. The tumor begins to shrink or break down over the subsequent weeks. Some tumors slough; others gradually involute. Pain management with NSAIDs such as carprofen for dogs or other prescribed analgesics is provided, along with wound care if there is open tissue.
Systemic side effects are uncommon because the systemic chemotherapy dose is so low. Mild lethargy and decreased appetite are sometimes reported for a few days. The veterinary team will outline expected progression with photos and provide a clear escalation plan if anything looks abnormal.
Response and Repeat Treatment
Some tumors respond completely to a single electrochemotherapy session; others require a second treatment scheduled four to eight weeks later. Tumor type, size, and location all influence the likelihood of complete response. Recurrence at the treatment site is possible and is monitored at follow-up visits with measurements, palpation, and sometimes imaging.
Veterinary published case series and small clinical trials have reported encouraging response rates for selected tumor types, though the evidence base is smaller than for established modalities such as conventional radiation. Your oncologist will frame expectations in terms of published response rates and median outcomes for similar tumors.
Cost and Access
Electrochemotherapy costs vary widely by region, specialty practice, anesthesia duration, and the number of treatment fields. Most procedures fall in a several-hundred to several-thousand dollar range, with multimodal cases reaching higher totals. Cost should be discussed up front as part of the consultation and treatment-planning process.
Access is the bigger constraint. Electrochemotherapy requires specialized equipment, trained operators, and an anesthesia team accustomed to oncology procedures. It is offered primarily at academic centers such as Colorado State, NC State, UC Davis, Penn Vet, Cornell, Tufts, and Texas A&M, and at a growing number of private specialty practices in major metro areas. If you are not within reasonable driving distance of a referral center, your primary veterinarian can help identify the nearest option and coordinate referral.
Comparing Electrochemotherapy to Other Modalities
For a tumor that can be removed with clean margins, surgery remains the cornerstone. For non-resectable tumors or those with positive margins, electrochemotherapy competes with conventional fractionated radiation, stereotactic body radiation therapy (SBRT), intratumoral therapies like Stelfonta, and systemic targeted therapy or chemotherapy. Each modality has distinct strengths and limitations.
Electrochemotherapy advantages include a single-procedure timeline, minimal systemic toxicity, and applicability where standard radiation may not be available or appropriate. Disadvantages include the depth limit, the anesthesia requirement, and the relatively limited number of centers offering it. The choice is best made in a multispecialty consultation that considers tumor biology, patient factors, and family priorities.
Adoption-Positive Framing
Dogs and cats with previously treated cutaneous or subcutaneous tumors, including those treated with electrochemotherapy, can be excellent adoption candidates. The key information to gather is the original biopsy histology and grade, the staging studies performed at diagnosis, the treatment plan executed, the time since last treatment, and the recommended monitoring schedule. With this information, an adopter can plan a realistic care budget and clinic relationship for ongoing follow-up.
For broader context on the cancers commonly addressed with this modality, see our overviews on mast cell tumors in dogs and cat injection site sarcoma.
Frequently Asked Questions
Is electrochemotherapy painful?
The procedure is performed under general anesthesia because the electric pulses cause muscle contractions and would be uncomfortable while delivered. Post-procedure soreness in the treated area is common for several days and is managed with prescribed pain medication. Most patients return to near-normal activity within a few days.
How is electrochemotherapy different from radiation?
Radiation uses ionizing energy to damage tumor DNA, typically delivered over many fractions or in concentrated stereotactic sessions. Electrochemotherapy uses electric pulses to dramatically enhance the entry of chemotherapy drugs into tumor cells in a single procedure. Both are local therapies, but the mechanism, equipment, scheduling, and side effect profile differ significantly.
Can electrochemotherapy treat internal tumors?
The standard veterinary application is for superficial tumors reachable with needle electrodes. Some centers are exploring intra-operative electrochemotherapy for tumors exposed at surgery, including liver and abdominal masses. This is an emerging area and is offered at very few specialty centers.
What does the success rate look like?
Published veterinary case series have reported encouraging complete and partial response rates for selected tumor types, particularly mast cell tumors and soft tissue sarcomas with positive surgical margins. Response varies by tumor type, size, and patient factors. Your oncologist will discuss expected response rates from the relevant literature for your specific situation.
Is electrochemotherapy considered standard of care?
Electrochemotherapy is well established in human dermatologic oncology and is supported by veterinary case series and emerging clinical data. It is considered an established option at the referral centers that offer it, particularly for tumors not amenable to surgery. It is not yet universally available, and the evidence base is still expanding compared with conventional modalities.